Industry update from Biotech Showcase.
Almost 16min
AML and Glioblastoma are both orphan disease's.
Orphan gene (he throws in cell) therapies are 3.5 times more likely to be approved once entering phase 1 trials than average drugs included in BIO's global trends in R&D 2023 report.
- 48% higher success rate in phase 1 clinical trials.
- 65% higher success rate in phase 2 clinical trials.
- 30% higher success rate in phase 3 clinical trials.
I dare say our early positive data puts us even higher.
Industry update from Biotech Showcase. Almost 16minAML and...
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
-0.002(6.90%) |
Mkt cap ! $23.12M | |||
| Open | High | Low | Value | Volume |
| 2.9¢ | 2.9¢ | 2.7¢ | $14.49K | 518.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1378548 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 158093 | 2 |
View Market Depth
| Last trade - 15.59pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
2.8¢ |
Change
-0.002 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 2.8¢ | 2.8¢ | 2.8¢ | 252061 | ||
| Last updated 15.47pm 06/05/2024 ? | |||||
| CHM (ASX) Chart |